Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Original Article

Association of triglyceride-glucose index with prognosis of COVID-19: A population-based study

Yoonkyung Chang\textsuperscript{a,1}, Jimin Jeon\textsuperscript{b,1}, Tae-Jin Song\textsuperscript{c,2}, Jinkwon Kim\textsuperscript{b,*}\textsuperscript{,3}

\textsuperscript{a} Department of Neurology, Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Republic of Korea
\textsuperscript{b} Department of Neurology, Yonin Severance Hospital, Yonsei University College of Medicine, Yongin-si, Republic of Korea
\textsuperscript{c} Department of Neurology, Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Republic of Korea

Abstract

Background: Triglyceride-glucose (TyG) index is a simple and reliable surrogate marker for insulin resistance. Epidemiology studies have shown that insulin resistance is a risk factor for various infectious diseases. We evaluated the prognostic value of TyG index measured before the COVID-19 infection in COVID-19 infected patients.

Methods: From a nationwide COVID-19 cohort dataset in Korea, we included COVID-19 patients diagnosed between Jan and Jun 2020. Based on the nationwide health screening data between 2015 and 2018, TyG index was calculated as ln [triglyceride (mg/dL) $\times$ fasting glucose level (mg/dL)]$^2$. Primary outcome is development of severe complications of COVID-19 defined as composite of mechanical ventilation, intensive care unit care, high-flow oxygen therapy, and mortality within two months after the diagnosis of COVID-19.

Results: This study included 3887 patients with COVID-19 confirmed by reverse transcription polymerase chain reaction. Mean $\pm$ standard deviation of TyG index was 8.54 $\pm$ 0.61. Severe complications of COVID-19 were noted in 289 (7.44%) patients. In the multivariate logistic regression, TyG index was positively associated with severe complications of COVID-19 (adjusted odds ratio: 1.42, 95% confidence interval [1.12–1.79]).

Conclusions: In COVID-19 infected patients, high TyG index was associated with increased risk for severe complications. TyG index might be useful predictor for the severity of COVID-19 infection.

© 2022 Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.

Background:

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. The global pandemic of COVID-19 is still ongoing and the most serious threat to public health in a century. Although most COVID-19 patients show good recovery, a number of patients, especially with underlying comorbidities, have critical complications including respiratory failure that can eventually lead to death [2]. Epidemiological studies have documented that the presence and number of comorbidities correlated with poorer outcome with COVID-19 infection [3]. Along with other comorbidities, diabetes mellitus was considered as a possible risk factor for COVID-19 infection and related complications [4].

Insulin resistance is the common metabolic disorder often associated with type 2 diabetes, representing a pathological condition in which the body’s cells become resistant to the hormone insulin [5]. Insulin involves multiple molecular and pathophysiological pathways, and pathologic condition of insulin resistance is closely linked to not only diabetes mellitus, but also to various medical conditions such as hypertension, dyslipidemia, liver disease, cardiovascular disease, neurodegenerative disease, malignancy, obesity, inflammatory and infectious disease [6,7]. In critically ill patients, insulin resistance has been reported to be correlated with the severity of condition and poor clinical outcome [8–10]. The triglyceride-glucose (TyG) index is a simple surrogate marker of insulin resistance, calculated using fasting triglyceride and fasting blood glucose.
glucose [11]. High TyG index is significant indicator of adverse prognosis in general population as well as in patients with various diseases [12,13]. We investigated whether TyG index measured before the COVID-19 infection has a prognostic value to identify those at high-risk for severe complications in COVID-19 infected patients.

Material and methods

Study design and participants

We performed a retrospective observational study for prognosis of COVID-19 infection according to TyG index with a nationwide population-based COVID-19 dataset in South Korea. South Korea has a single-payer public healthcare system, called by National Health Insurance Service (NHIS). NHIS has an information for hospital visit, diagnoses (recorded based on International Statistical Classification of Diseases and Related Health Problems 10th revision), medical procedure, prescription, and mortality of the whole Korean population [14]. Recently, the Korea Centers for Disease Control and Prevention, and the Ministry of Health and Welfare, South Korea released a nationwide COVID-19-related dataset, which includes the data of Korean citizens who underwent real-time reverse transcription polymerase chain reaction (RT-PCR) assays with nasal and pharyngeal swabs to COVID-19 from January 1 to June 4, 2020 [15]. The COVID-19-related dataset contains data on result of COVID-19 test (positive or negative), national health check-up program (2015–2018), health claims data, and mortality of all people who underwent RT-PCR tests for the COVID-19 [16]. The real-time PT PCR assays kit followed the WHO guideline and was validated by the Korea Centers for Disease Control and Prevention [17].

TyG index and covariates

As a public institution, the NHIS provides free health checkups to all Koreans aged ≥ 40 years every two years. The free health checkups program consisted of physical examination of blood pressure, body mass index (BMI), lifestyle survey (medical history, physical activity, smoking habit, alcohol consumption), and laboratory tests including fasting glucose, triglyceride, cholesterol levels [18]. The TyG index was calculated as In [triglyceride (mg/dL) × fasting glucose level (mg/dL)]/2, based on the blood chemistry data measured in the free nationwide health checkups program before the COVID-19 infection (2015–2018) [19]. In order to avoid errors due to extreme values, when the measured value ≥ 99th percentile value or ≤ 1 percentile value, they are replaced with the 99th percentile value or the 1 percentile value, subsequently. If study participants underwent twice or more health check-up during the period, the most recent data was used in this study.

From the health claims and health checkups program data, we also collected information for sex, age at COVID-19 diagnosis, household income level (four quartiles), alcohol consumption, smoking habit, physical activity, BMI, low density lipoprotein (LDL) cholesterol, and presence of comorbidities (hypertension, diabetes mellitus, stroke, coronary artery disease, chronic kidney disease, asthma, malignancy). BMI was calculated by one’s weight (kg) divided by the square of height (m²). Hypertension was defined when participants received prescription blood pressure lowering agents (calcium-channel blocker, diuretics, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, and beta-blockers) with hypertension diagnostic codes of ‘110–115’, or had blood pressure ≥ 140/90 mmHg, or positive checking in a self-report questionnaire regarding hypertension [20]. Diabetes mellitus was defined when participants had received prescription anti-diabetic agents (sulphonylurea, metformin, meglitinide, thiazolidinedione, dipeptidyl peptidase-4 inhibitor, sodium-glucose co-transporter 2, glucagon-like peptide-1 agonists, α-glucosidase inhibitor, and insulin) with diabetes mellitus diagnostic codes of ‘E11–14’, or had fasting blood glucose > 7.0 mmol/L, or positive checking in a self-report questionnaire for diabetes mellitus. Stroke was defined as the presence of corresponding stroke diagnostic codes of ‘I60–I63’, ‘I69’. Coronary artery disease and chronic kidney disease were defined as the presence of corresponding diagnostic codes (coronary artery disease: I20–25, chronic kidney disease: N03, N05, N165, N18–19, N250, I12–13, Z490, Z491–2, Z940, Z992, E102, E112, E132, E142, or T861) [21,22]. Asthma was determined by the presence of diagnostic codes of ‘J45–46’ as the primary diagnosis 2 times or more [23]. Malignancy was defined by having at least three times outpatient visits or once admission with the diagnostic code of ‘C00–97’ with specific cancer registration code of ‘V027’, ‘V193–4’. The data for smoking habit (current, former, never), alcohol consumption (average frequency per week: < 1 time, 1–2 times, 3–4 times or ≥5 times), and physical activity (average frequency per week: < 1 day, 1–4 days or ≥5 days) were obtained from the self-report questionnaire for lifestyle in the health check-up program.

Study outcomes

We defined the primary outcome as a composite of 1) application of mechanical ventilation, 2) admission to the intensive care unit, 3) use of high-flow oxygen therapy, and 4) mortality within 2 months after COVID-19 diagnosis. Application of mechanical ventilation was identified by claim codes for mechanical ventilation (M5850, M5857, M5858, M5860). The admission to the intensive care unit was defined using the related claim codes for intensive care (AH110, AH115, AH180–5, AH190–5, AH210, AH250, AH280–9, AH28A, AH290–9, AH380–9, AH38A, AH390–9, AH501, AJ001–AJ011, AJ020–1, AJ031, AJ100–390, AJ2A0, AJ3A0, AJ500–590, V5100, V5200, V5210–20, V5500–5520). High-flow oxygen therapy was determined by the presence of claim code for high-flow nasal cannula therapy (M0046) [24]. Mortality data are obtained by NHIS, which have previously been validated [25].

Statistical analyses

For comparison of continuous and categorical variables between groups, independent t-tests and chi-square tests were performed, respectively. To evaluate the relationship between TyG index and severe complications of COVID-19 infection, we used univariable and multivariable logistic regression analyses. To detect and measure the collinearity in a multivariable regression model, we calculated variance inflation factor (VIF) for each variable. Small value of VIF indicates low correlation among variables and it is believed acceptable if it is less than 5 [26]. The subgroup analyses were conducted according to the sex, age (dichotomized more than 60 years old), history of hypertension, and history of diabetes mellitus. The results were presented as odds ratio (OR) and 95% confidence interval (CI). To help the understanding of the association between TyG index and COVID-19 outcomes, we draw a spline curve representing OR for primary outcome according to the continuous level of TyG index. All statistics were executed using R software, version 3.3.3 (R Foundation for Statistical Computing, Vienna, Austria), and SAS 9.4 version (SAS Inc., Cary, NC, USA). Two-sided P-values less than 0.05 were considered significant.

Results

Participants and demographics

The Korean nationwide COVID-19 cohort consisted of 212,678 participants aged ≥ 20 years who received RT-PCR test for COVID-19. Among them, 7713 patients who tested positive in the COVID-19 PCR test were included in this study, excluding those who tested negative...
in the COVID-19 PCR test (n = 204,965). Among these 7713 patients, there were 3934 patients who had available data for national health screening program in 2015–2018. We additionally excluded 47 patients with incomplete data for analysis. Finally, 3887 patients with confirmed COVID-19 diagnosis were included in this study (Fig. 1).

Among the finally included 3887 patients, 1451 (37.33%) were male and 1520 (39.10%) were ≥ 60 years of age. The mean ± standard deviation of fasting glucose and triglyceride was 100.44 ± 22.87 mg/dL and 120.04 ± 73.46 mg/dL, respectively. Demographics, comorbidities, and laboratory findings are presented in Table 1. Compared to the group without severe complications, the severe complications of COVID-19 group were older and had a higher BMI (24.79 ± 3.43 vs. 23.91 ± 3.27 kg/m², p < 0.001). Comorbidities such as hypertension, diabetes mellitus, stroke, and coronary artery disease, chronic kidney disease, asthma, and malignancy were more commonly noted in severe complications of COVID-19 group. The severe complications of COVID-19 group had a higher TyG index than the group without severe complications (8.81 ± 0.61 vs. 8.51 ± 0.61, p < 0.001), and fasting glucose level (111.64 ± 29.65 vs. 99.54 ± 22.00 mg/dL, p < 0.001) and triglyceride (142.58 ± 84.51 vs. 118.22 ± 72.20 mg/dL, p < 0.001) were higher (Table 1).

Association of TyG index with severe complications of COVID-19

Primary outcome for severe complications of COVID-19 was noted in 289 (7.44%) patients including mechanical ventilation in 119 (3.06%) patients, intensive care unit care in 171 (4.40%) patients, high-flow oxygen therapy in 83 (2.14%) patients, and mortality in 114 (2.93%) patients, respectively. After adjusting sex, age, household income, alcohol consumption, smoking habit, physical activity, BMI, hypertension, diabetes mellitus, stroke, coronary artery disease, chronic kidney disease, asthma, malignancy, and LDL cholesterol, TyG index was positively associated with severe complications of COVID-19 (OR: 1.42, 95% CI [1.12 – 1.79], p = 0.003) (Table 2). In a testing for multicollinearity with VIF, all values are < 2 indicating absence of high multicollinearity.

Distribution of TyG index according to the presence of severe complications of COVID-19 are demonstrated in Fig. 2. A spline curve demonstrated the positive association between TyG index and severe complications of COVID-19 (Fig. 3). In subgroup analysis by sex, age, hypertension, and diabetes mellitus, the positive association of TyG index with severe complications of COVID-19 was consistently noted (all p for interaction > 0.05, Fig. 4).

Discussion

The key finding of our study based on a nationwide population-based COVID-database in South Korea is that high TyG index, which represents insulin resistance, was associated with the increased risk for severe complications of COVID-19 patients.

In a previous hospital-based study with 151 COVID-19 positive patients, the TyG index levels were significantly higher in the patients with severe complication or mortality [27]. Among patients
hospitalized for COVID-19, those with critical COVID-19 presented higher levels of fasting glucose, triglycerides, both of which are components of the TyG index [28]. Another hospital-based case-control study with 43 patients revealed that biochemical markers of insulin resistance may be related with severe complications of COVID-19 [29].

Our result is in line with these previous studies for the potential role of TyG index and markers of insulin resistance as an indicator for the severe complications of COVID-19 [27]. Unlike the prior studies, we calculated TyG index based on a nationwide health screening data measured before the COVID-19 infection. It has been known that COVID-19 infection itself can induce insulin resistance and lipid metabolic dysregulation [30, 31]. The previous case series demonstrated that COVID-19 infection triggered uncontrolled hyperglycemia and insulin resistance in acute phase [32–34]. Therefore, worse prognosis of COVID-19 patients with high TyG index measured in acute phase might be due to that critical illness with COVID-19 infection itself cause further insulin resistance [35]. We found that the TyG index measured before the COVID-19 infection also had a significant association with COVID-19 prognosis. This result added evidence that underlying insulin resistance in health condition is one of determinant for the prognosis of COVID-19 infection. Regarding the interplay between inflammation and insulin resistance, baseline insulin resistance may hold key to improving immune responses against COVID-19 [36]. In addition, our study showed that TyG index easily calculated from a pre-existing blood test can serve as a simple tool to predict the risk of severe complications from COVID-19 without additional test. It will be applicable to screening those at high-risk in general population who need to pay more attention to COVID-19 infection and determining priority group for COVID-19 vaccination.

Although our study is not a study for the mechanism, we may allow proposing hypotheses that may explain the association between the TyG index and severe COVID-19 outcome. TyG index was associated with metabolic syndrome, dyslipidemia, future development of diabetes mellitus, subclinical coronary artery disease, arterial stiffness, and occurrence of major cardiovascular events [11, 37, 38]. Epidemiologic data have documented that individuals with high TyG index are at increased risk for nonalcoholic fatty liver disease, which is also closely related to obesity and insulin resistance [39, 40]. It has been established that the presence and number of these comorbidities in COVID-19 patients, which closely related with

| Table 1 Baseline characteristics of COVID-19 patients according to prognosis. |
|-------------------------------|-----------------------------|-----------------------------|
| Variable                      | Total                       | Without Severe complications of COVID-19 | With Severe complications of COVID-19 |
|-------------------------------|-----------------------------|------------------------------------------|---------------------------------------|
| Number of patients            | 3887                        | 3598                                     | 289                                   |
| Sex, male                     | 1451 (37.33)                | 1275 (35.44)                             | 176 (60.90)                            |
| Age, years                    |                             |                                          |                                       |
| < 60                          | 2367 (60.90)                | 2307 (64.12)                             | 60 (20.76)                             |
| ≥ 60                          | 1520 (39.10)                | 1291 (35.88)                             | 229 (79.24)                            |
| Household income              |                             |                                          |                                       |
| Q1, lowest                    | 1320 (33.96)                | 1241 (34.49)                             | 79 (27.34)                             |
| Q2                            | 912 (23.46)                 | 852 (23.68)                              | 60 (20.76)                             |
| Q3                            | 705 (18.14)                 | 651 (18.09)                              | 54 (18.69)                             |
| Q4, highest                   | 950 (24.44)                 | 854 (23.74)                              | 96 (33.22)                             |
| Alcohol consumption, frequency per week |                  |                                          |                                       |
| < 1 time                      | 2656 (68.33)                | 2442 (67.87)                             | 214 (74.05)                            |
| 1–2 times                     | 921 (23.69)                 | 880 (24.46)                              | 41 (14.19)                             |
| 3–4 times                     | 225 (5.79)                  | 198 (5.50)                               | 27 (9.34)                              |
| ≥ 5 times                     | 85 (2.19)                   | 78 (2.17)                                | 7 (2.42)                               |
| Smoking habit                 |                             |                                          |                                       |
| None                          | 3018 (77.64)                | 2840 (78.93)                             | 178 (61.59)                            |
| Former smoker                 | 573 (14.74)                 | 481 (13.37)                              | 92 (31.83)                             |
| Current smoker                | 296 (7.62)                  | 277 (7.70)                               | 19 (6.57)                              |
| Physical activity, frequency per week |                  |                                          |                                       |
| < 1 day                       | 806 (20.74)                 | 730 (20.29)                              | 76 (26.30)                             |
| 1–4 days                      | 1693 (43.56)                | 1586 (44.08)                             | 107 (37.02)                            |
| ≥ 5 days                      | 1388 (35.71)                | 1282 (35.63)                             | 106 (36.68)                            |
| Anthropometric measurements   |                             |                                          |                                       |
| Body mass index (kg/m²)       | 23.97 ± 3.29                | 23.91 ± 3.27                             | 24.79 ± 3.43                           |
| Comorbidities                 |                             |                                          |                                       |
| Hypertension                  | 1304 (33.55)                | 1115 (30.99)                             | 189 (65.40)                            |
| Diabetes mellitus             | 601 (15.45)                 | 502 (13.95)                              | 99 (34.26)                             |
| Stroke                        | 156 (4.01)                  | 123 (3.42)                               | 33 (11.42)                             |
| Coronary artery disease       | 209 (5.38)                  | 172 (4.78)                               | 37 (12.80)                             |
| Chronic kidney disease        | 278 (7.15)                  | 230 (6.39)                               | 48 (16.61)                             |
| Asthma                        | 212 (5.45)                  | 185 (5.14)                               | 29 (9.34)                              |
| Laboratory findings           |                             |                                          |                                       |
| Fasting glucose, mg/dL        | 100.44 ± 22.87              | 99.54 ± 22.00                            | 111.64 ± 29.65                         |
| Triglyceride, mg/dL           | 120.04 ± 73.46              | 118.22 ± 72.20                           | 142.58 ± 84.51                         |
| LDL cholesterol, mg/dL        | 114.23 ± 33.03              | 114.83 ± 32.64                           | 106.74 ± 34.46                         |
| TyG index                     | 8.54 ± 0.61                 | 8.51 ± 0.61                              | 8.81 ± 0.61                            |
| Clinical outcome              |                             |                                          |                                       |
| Mechanical ventilation        | 119 (3.06)                  |                                          |                                       |
| Intensive care unit care      | 171 (4.40)                  |                                          |                                       |
| High-flow oxygen therapy      | 81 (2.14)                   |                                          |                                       |
| Mortality                     | 114 (2.93)                  |                                          |                                       |

Data are represented as number of patients (%) or mean ± standard deviation. Q, quartile; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; TyG index is calculated by the following formula: ln [fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2].

* Primary outcome is composite of mechanical ventilation, intensive care unit care, high-flow oxygen therapy, and mortality within two months after COVID-19 diagnosis

b P-value is derived from independent t-test or Chi’s square test between patient groups according to primary outcome.
Table 2
Association factors for occurrence of severe complications in COVID-19 patients.

| Variable                                           | Univariate OR [95% CI] | P-value  | Adjusted OR [95% CI] | P-value |
|----------------------------------------------------|------------------------|----------|----------------------|---------|
| Sex, male                                          | 2.84 [2.22–3.63]       | < 0.001  | 2.40 [1.72–3.34]     | < 0.001 |
| Age, years                                         |                        |          |                      |         |
| < 60                                               | 1 (Ref)                | –        | 1 (Ref)              | –       |
| ≥ 60                                               | 6.82 [5.09–9.14]       | < 0.001  | 3.89 [2.81–5.37]     | < 0.001 |
| Household income                                   |                        |          |                      |         |
| Q1, lowest                                         | 1 (Ref)                | –        | 1 (Ref)              | –       |
| Q2                                                 | 1.11 [0.78–1.57]       | 0.568    | 1.15 [0.79–1.66]     | 0.474   |
| Q3                                                 | 1.30 [0.91–1.87]       | 0.148    | 1.17 [0.80–1.72]     | 0.422   |
| Q4, highest                                        | 1.77 [1.30–2.41]       | < 0.001  | 1.42 [1.02–1.99]     | 0.040   |
| Alcohol consumption, frequency per week            |                        |          |                      |         |
| < 1 time                                           | 1 (Ref)                | –        | 1 (Ref)              | –       |
| 1–2 times                                          | 0.53 [0.38–0.75]       | < 0.001  | 0.52 [0.35–0.77]     | 0.001   |
| 3–4 times                                          | 1.56 [1.02–2.38]       | 0.042    | 0.95 [0.58–1.57]     | 0.851   |
| ≥ 5 times                                          | 1.02 [0.47–2.25]       | 0.953    | 0.46 [0.20–1.07]     | 0.072   |
| Smoking habit                                      |                        |          |                      |         |
| None                                               | 1 (Ref)                | –        | 1 (Ref)              | –       |
| Former smoker                                      | 3.05 [2.33–4.00]       | < 0.001  | 1.53 [1.07–2.21]     | 0.021   |
| Current smoker                                     | 1.09 [0.67–1.78]       | 0.718    | 0.67 [0.38–1.17]     | 0.155   |
| Physical activity, frequency per week              |                        |          |                      |         |
| < 1 day                                            | 1 (Ref)                | –        | 1 (Ref)              | –       |
| 1–4 days                                           | 0.65 [0.48–0.88]       | 0.006    | 0.77 [0.55–1.07]     | 0.124   |
| ≥ 5 days                                           | 0.79 [0.58–1.08]       | 0.142    | 0.80 [0.57–1.12]     | 0.199   |
| Anthropometric measurements                        |                        |          |                      |         |
| Body mass index (kg/m^2)                           | 1.08 [1.04–1.12]       | < 0.001  | 1.01 [0.97–1.06]     | 0.586   |
| Comorbidities                                      |                        |          |                      |         |
| Hypertension                                       | 4.21 [3.27–5.42]       | < 0.001  | 1.78 [1.33–2.39]     | < 0.001 |
| Diabetes mellitus                                  | 3.21 [2.48–4.17]       | < 0.001  | 1.20 [0.87–1.66]     | 0.261   |
| Stroke                                             | 3.64 [2.43–5.46]       | < 0.001  | 1.25 [0.80–1.96]     | 0.326   |
| Coronary artery disease                            | 2.93 [2.01–4.27]       | < 0.001  | 1.21 [0.79–1.83]     | 0.386   |
| Chronic kidney disease                             | 2.92 [2.08–4.09]       | < 0.001  | 1.27 [0.86–1.88]     | 0.225   |
| Asthma                                             | 1.50 [1.25–2.90]       | 0.003    | 1.33 [0.84–2.12]     | 0.222   |
| Malignancy                                         | 2.06 [1.46–2.90]       | < 0.001  | 1.36 [0.93–1.99]     | 0.115   |
| Laboratory findings                                |                        |          |                      |         |
| LDL cholesterol, mmol/L                            | 0.87 [0.82–0.93]       | < 0.001  | 0.93 [0.86–0.99]     | 0.032   |
| Triglyceride/glucose index                         | 2.11 [1.75–2.54]       | < 0.001  | 1.42 [1.12–1.79]     | 0.003   |

Data are derived from logistic regression analysis for severe complications of COVID-19. Severe complications of COVID-19 are composite of mechanical ventilation, intensive care unit care, high-flow oxygen therapy, and mortality.

OR, odds ratio; CI, confidence interval; Q, quartile; LDL, low-density lipoprotein.

* Adjusted for sex, age, household income, alcohol consumption, smoking status, physical activity, body mass index, hypertension, diabetes mellitus, stroke, coronary artery disease, chronic kidney disease, asthma, malignancy, and LDL cholesterol.

Fig. 2. Distribution of triglyceride-glucose index according to presence of severe complications of COVID-19. Vertical dotted lines present the mean values of triglyceride-glucose index in each groups with and without severe complications of COVID-19.

Fig. 3. Spline curve of the association between triglyceride-glucose index and severe complications of COVID-19. The black lines and gray shadows represent the odds ratio and 95% confidence intervals for the presence of severe complications of COVID-19 (composite of mechanical ventilation, intensive care unit care, high-flow oxygen therapy, and mortality). Ref indicates median value (8.49) of triglyceride-glucose index. TyG, triglyceride-glucose index; CI: confidence interval.
insulin resistance and TyG index, are associated with poor prognosis of COVID-19 [38,41,42]. Because TyG index is considered a good surrogate marker of the comorbidities, those with high TyG index may have more risk factors and worse clinical outcomes in COVID-19 patients [27].

In COVID-19 infection, immunologic response plays a key role to maintain health and pathogenesis [43]. Current evidence suggested that dysregulated immune response may be responsible for COVID-19 pathogenesis and related critical illness, including lymphopenia, neutrophilia, dysregulation of monocytes/macrophages, impaired type I interferon response, antibody-dependent enhancement, and cytokine storm [44,45]. Studies in insulin resistance have revealed a clear association between the chronic activation of pro-inflammatory signaling pathways/impaired immune response and decreased insulin sensitivity [46,47]. Macrophages chronically exposed to high levels of insulin result in sustained inflammatory cytokine production and altered response to pathogen [48]. It has become apparent that the impaired immune response through multiple pathways in insulin resistance can lead to systemic alterations contributing to excessive production of pro-inflammatory cytokines, also known as a cytokine storm [36,49]. Because hyper-activated inflammatory responses with cytokine storm occurring in COVID-19 are regarded major pathogenesis of critical illness with COVID-19 [50], chronic activation of pro-inflammatory signaling and altered immunologic response with insulin resistance, presented as high TG index, could be a predisposing factor for severe complications of COVID-19 [27]. Accordingly, viremia may be worsened by insulin resistance, and this increased risk of viremia may cause poor prognosis or morality after COVID-19 infection [51,52].

Our study has limitations. First, because our study had a retrospective cohort design, the causal relationship could not be proven. Second, in the health screening cohort, young people under the age of 40 could not be included, so there would be a selection bias. Third, it is difficult to generalize our results for overall ethnicity because our dataset consists of only the Korean general population. Fourth, because our dataset checked the lipid profile before the COVID-19 infection, there was a lack of the serial laboratory finding or the change of the lipid profile after COVID-19. Fifth, concurrent medications before and after COVID-19 infection might be a possible confounding factor on the prognosis, which were not evaluated in current study. Since the TyG index is the calculated product of fasting triglyceride level and fasting blood glucose level, it could be affected by the anti-diabetic or lipid-lowering agents taken at the time of health screening. Finally, since insulin levels were not measured in our nationwide screening dataset, we could not directly check the insulin resistance.

In conclusion, our study demonstrated that TyG index measured before the COVID-19 infection was significantly associated with increased risk for severe complications of COVID-19. TyG index, which is simply calculated from fasting triglyceride and fasting blood glucose, may be a useful prognostic biomarker in COVID-19 infection. Further study is need for the pathophysiologic linking between insulin resistance and COVID-19 adverse outcomes.

Funding

This study was supported by a new faculty research seed money grant of Yonsei University College of Medicine for 2022 (2022-22-0058). This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2020R1I1A1A01060447 to JK, 2021R1F1A1048113 to T-JS, 2021R1I1A1A01059868 to YC). The funders had no role in study design, data collection and analysis, the decision to publish, or preparation of the manuscript.

Ethics approval

The NHIS data was fully anonymized for privacy protection. Due to the retrospective analysis based on the fully anonymized data from our dataset, this study was approved by the Institutional Review Board of our institution (Seoul Hospital Ewha Womans University College of Medicine 2020-10-021), and the requirement for informed consent was waived.
Data availability

The COVID-19 database used in the present study is available from the National Health Insurance Sharing Service [http://nhiss.nhis.or.kr/bd/ab/bdaba201英格兰], but restrictions apply to the availability of these data, which were used under licence for the current study and so are not publicly available. To access the data, a complete application form, research proposal, and an approval document for research purposes from an institutional review board should be submitted to the NHIS for review by the inquiry committee of research support.

Declaration of Competing Interest

The authors declare no conflicts of interest.

Acknowledgments

This study used the COVID-19 dataset (NHIS-2021-1-347) created by NHIS.

Author’s contributions

Tae-Jin Song and Yoonkyung Chang designed the research and the interpretation of data. Tae-Jin Song and Jinkwon Kim participated in the interpretation of all data and the critical revision of the manuscript for intellectual content. All authors read and approved the manuscript.

References

[1] Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021;19(3):141–54. https://doi.org/10.1038/s41579-020-00495-7
[2] Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect 2020;81(2):e16–25. https://doi.org/10.1016/j.jinf.2020.04.021
[3] Liu W, Yang C, Liao YG, Wan F, Lin L, Huang X, et al. Risk factors for COVID-19 progression and mortality in hospitalized patients without pre-existing comorbidities. J Infect Public Health 2022;15(1):13–20. https://doi.org/10.1016/j.jiph.2021.11.012
[4] Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol 2021;17(1):11–30. https://doi.org/10.1038/s41574-020-00435-4
[5] Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 2001;109(Suppl 2):S135–48. https://doi.org/10.1055/s-0028-1087576
[6] Singh B, Saxena A. Surrogate markers of insulin resistance: a review. World J Diabetes 2010;1(2):36–47. https://doi.org/10.4236wj.d.2011.12.36
[7] Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005;42(5):978–1000. https://doi.org/10.1002/hep.20290
[8] Ilia S, Diamantopoulos A, Pratikaki M, Boulouza E, Jahajh E, Athanasiou N, et al. Glycemia, beta-cell function and sensitivity to insulin in mildly to critically ill COVID-19 patients. Medicina 2021;57(1). https://doi.org/10.3390/medicina57000068
[9] Trifunovic D, Stankovic S, Sobic-Sarajev D, Marinkovic J, Petrovic M, Orlic D, et al. Acute insulin resistance in ST-segment elevation myocardial infarction in non-diabetic patients is associated with incomplete myocardial reperfusion and impaired coronary microcirculatory function. Cardiovasc Diabetol 2014;13:73. https://doi.org/10.1186/1475-2840-13-73
[10] Preiser JC, Ichai C, Orban JC, Groeneveld AB. Metabolic response to the stress of COVID-19. Hypertension 2020;76(3):742–9. https://doi.org/10.1161/HYPERTENSIONAHA.120.15464
[11] Song TJ, Jeon J, Kim K. Cardiovascular risks of prednisolone and oral insulin injections in COVID-19 patients with diabetes mellitus. Diabetes Metab 2021;47(6):101252. https://doi.org/10.1016/j.diabetem metab.2021.101252
[12] Neter J, Kutner M.H., Nachtsheim C.J., Wasserman W. Applied linear statistical models. 1996.
[13] Ren H, Yang Y, Wang F, Yan Y, Shi X, Dong K, et al. Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19. Cardiovasc Diabetol 2020;19(1):1. https://doi.org/10.1186/s12933-020-01035-2
[14] Bellia A, Andreadi A, Giudice L, De Teddeo S, Maiorino A, D’Ippolito I, et al. Athospheromic dyslipidemia in COVID-19 patients with poor outcomes in people with and without diabetes hospitalised for COVID-19. Diabetes Care 2021;44(9):2149–57. https://doi.org/10.2337/dc20-2838
[15] Alcántara-Alonso E, Molinero R, Gómez-J女神 A, Alcántara-Alonso V, Muñoz-Pérez MA, Lozano-Marín J, et al. High triglyceride to HDL-cholesterol ratio as a biochemical marker of severe outcomes in COVID-19 patients. Clin Nutr Esp 2021;43:47–44. https://doi.org/10.1016/j.clin.esp.2020.04.020
[16] Goméz-Álvarado N, Khaled Q, Moody C, Naicher H. Insulin resistance in COVID-19 and diabetes. Prim Care Diabetes 2021;15(4):629–34. https://doi.org/10.1016/j.pcd.2021.04.004
[17] Chen M, Zhu B, Chen D, Hu X, Xu X, Shen W, et al. COVID-19 may increase the risk of insulin resistance in adult patients without diabetes: a 6-month prospective study. Endocr Pract 2021;27(8):834–41. https://doi.org/10.9779/ej.ep.2021.04.004
[18] Affinati AH, Wallia A, Gianchandani RY. Severe hyperglycaemia and insulin resistance in patients with SARS-CoV-2 infection: a report of two cases. Clin Diabetes Endocrinol 2021;7(1):8. https://doi.org/10.1080/204842021-00121-y
[19] Sogegeli SA, Ingram CC, Crawley S, Low Wang CC. Insulin resistance in a hospitalized COVID-19 patient: a case report. Clin Diabetics 2021;39(2):28–32. https://doi.org/10.1007/s13290-020-00098-3
[20] Jornayvaz FR, Assouline B, Pugin J, Gariani K. Extremely high-dose insulin requirement in a diabetic patient with COVID-19: a case report. BMC Endocr Disord 2020;20(1):155. https://doi.org/10.1186/s12902-020-00632-2
[21] Langschei L, Van den Berge G, Gunst J. Hyperglycaemia and insulin resistance in COVID-19 versus non-COVID critical illness: are they really different. Crit Care 2021;25(1):417. https://doi.org/10.1186/s13054-021-03861-6
[22] Gangadharan C, Ahluwalia R, Sigamani A. Diabetes and COVID-19: role of insulin resistance as a risk factor for COVID-19 severity. World J Diabetes 2021;12(9):1550–62. https://doi.org/10.4233/wjd.v12i9.1550
[23] Chamorro-kiuflun F, Ananchaissak T, Wananichawon W. The triglyceride-glucose index, a predictor of type 2 diabetes development: a retrospective cohort study. Prim Care Diabetes 2016;10(4):167–71. https://doi.org/10.1016/j.pcd.2015.04.004
[24] Park GM, Cho YR, Won KB, Yang YJ, Ann SH, et al. Triglyceride glucose index is a useful marker for predicting subclinical coronary artery disease in the absence of traditional risk factors. Lipids Health Dis 2020;19(1):7. https://doi.org/10.1186/s12944-020-1187-0
Kitae A, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. The triglyceride and glucose index is a predictor of incident nonalcoholic fatty liver disease: a population-based cohort study. Can J Gastroenterol Hepatol 2019;2019:5121574. https://doi.org/10.1155/2019/5121574

Zhang S, Du T, Zhang J, Lu H, Lin X, Xie J, et al. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis 2017;16(1):15. https://doi.org/10.1186/s12944-017-0409-6

Luo E, Wang D, Van G, Qiao Y, Liu B, Hou J, et al. High triglyceride-glucose index is associated with poor prognosis in patients with acute ST-elevation myocardial infarction after percutaneous coronary intervention. Cardiovasc Diabetol 2019;18(1):150. https://doi.org/10.1186/s12933-019-0957-3

Liu D, Zheng Y, Kang J, Wang D, Bai L, Mao Y, et al. Not only high number and specific comorbidities but also age are closely related to progression and poor prognosis in patients with COVID-19. Front Med 2021;8:736109. https://doi.org/10.3389/fmed.2021.736109

Chowdhury MA, Hossain N, Kashem MA, Alam A. Immune response in COVID-19: a review. J Infect Public Health 2020;13(11):1619–29. https://doi.org/10.1016/j.jiph.2020.07.001

Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther 2021;6(1):255. https://doi.org/10.1038/s41392-021-00679-0

Sharma SK, Bhart P, Asdaq SMB, Alshammari MK, Alanazi A, Alrasheedi NS, et al. Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: a narrative review. J Infect Public Health 2022. https://doi.org/10.1016/j.jiph.2022.03.014

de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett 2008;582(1):97–105. https://doi.org/10.1016/j.febslet.2007.11.057

Rehman K, Akash MS. Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked. J Biomed Sci 2016;23(1):47. https://doi.org/10.1186/s12929-016-0303-y

Ieronymaki E, Daskalaki MG, Lyroni K, Tsatsanis C. Insulin signaling and insulin resistance facilitate trained immunity in macrophages through metabolic and epigenetic changes. Front Immunol 2019;10:1330. https://doi.org/10.3389/fimmu.2019.01330

Damiati LA, Bahsali S, Aljohaney A, Bawazir Y, Mustafa M, Denetiu I, et al. Implications of SARS-CoV-2 infection on the clinical, hematological, and inflammatory parameters in COVID-19 patients: a retrospective cross-sectional study. J Infect Public Health 2022;15(2):214–21. https://doi.org/10.1016/j.jiph.2021.12.013

Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 2020;20(6):355–62. https://doi.org/10.1038/s41577-020-0331-4

Finucane FM, Davenport C. Coronavirus and obesity: could insulin resistance mediate the severity of Covid-19 infection. Front Public Health 2020;8(184). https://doi.org/10.3389/fpubh.2020.00184

Myhre PL, Prebensen C, Jonassen CM, Berdal JE, Omland T. SARS-CoV-2 viremia is associated with inflammatory, but not cardiovascular biomarkers, in patients hospitalized for COVID-19. J Am Heart Assoc 2021;10(9):e019756. https://doi.org/10.1161/JAHA.120.019756